PMID- 21276769
OWN - NLM
STAT- MEDLINE
DCOM- 20110620
LR  - 20211020
IS  - 1096-0309 (Electronic)
IS  - 0003-2697 (Print)
IS  - 0003-2697 (Linking)
VI  - 412
IP  - 1
DP  - 2011 May 1
TI  - Molecular imaging of c-Met tyrosine kinase activity.
PG  - 1-8
LID - 10.1016/j.ab.2011.01.028 [doi]
AB  - The receptor tyrosine kinase c-Met and its ligand, hepatocyte growth 
      factor/scatter factor (HGF/SF), modulate signaling cascades implicated in 
      cellular proliferation, survival, migration, invasion, and angiogenesis. 
      Therefore, dysregulation of HGF/c-Met signaling can compromise the cellular 
      capacity to moderate these activities and can lead to tumorigenesis, metastasis, 
      and therapeutic resistance in various human malignancies. To facilitate studies 
      investigating HGF/c-Met receptor coupling or c-Met signaling events in real time 
      and in living cells and animals, here we describe a genetically engineered 
      reporter where bioluminescence can be used as a surrogate for c-Met tyrosine 
      kinase activity. c-Met kinase activity in cultured cells and tumor xenografts was 
      monitored quantitatively and dynamically in response to the activation or 
      inhibition of the HGF/c-Met signaling pathway. Treatment of tumor-bearing animals 
      with a c-Met inhibitor and the HGF neutralizing antibody stimulated the 
      reporter's bioluminescence activity in a dose-dependent manner and led to a 
      regression of U-87 MG tumor xenografts. Results obtained from these studies 
      provide unique insights into the pharmacokinetics and pharmacodynamics of agents 
      that modulate c-Met activity and validate c-Met as a target for human 
      glioblastoma therapy.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Zhang, Limin
AU  - Zhang L
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Virani, Shama
AU  - Virani S
FAU - Zhang, Yu
AU  - Zhang Y
FAU - Bhojani, Mahaveer S
AU  - Bhojani MS
FAU - Burgess, Teresa L
AU  - Burgess TL
FAU - Coxon, Angela
AU  - Coxon A
FAU - Galban, Craig J
AU  - Galban CJ
FAU - Ross, Brian D
AU  - Ross BD
FAU - Rehemtulla, Alnawaz
AU  - Rehemtulla A
LA  - eng
GR  - P50 CA093990-10/CA/NCI NIH HHS/United States
GR  - P01 CA085878-09/CA/NCI NIH HHS/United States
GR  - U24CA083099/CA/NCI NIH HHS/United States
GR  - U24 CA083099/CA/NCI NIH HHS/United States
GR  - R01 CA129623/CA/NCI NIH HHS/United States
GR  - U24 CA083099-10/CA/NCI NIH HHS/United States
GR  - R01CA129623/CA/NCI NIH HHS/United States
GR  - P01CA085878/CA/NCI NIH HHS/United States
GR  - P50CA093990/CA/NCI NIH HHS/United States
GR  - R01 CA129623-05/CA/NCI NIH HHS/United States
GR  - P01 CA085878/CA/NCI NIH HHS/United States
GR  - P50 CA093990/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110127
PL  - United States
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
RN  - 0 (Antibodies, Neutralizing)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Animals
MH  - Antibodies, Neutralizing/immunology
MH  - Cell Line, Tumor
MH  - Genes, Recessive
MH  - Glioblastoma/therapy
MH  - Hepatocyte Growth Factor/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Molecular Imaging/*methods
MH  - Proto-Oncogene Proteins c-met/*metabolism/therapeutic use
MH  - Signal Transduction
MH  - Transplantation, Heterologous
PMC - PMC3265038
MID - NIHMS269035
EDAT- 2011/02/01 06:00
MHDA- 2011/06/21 06:00
PMCR- 2012/05/01
CRDT- 2011/02/01 06:00
PHST- 2010/08/31 00:00 [received]
PHST- 2011/01/14 00:00 [revised]
PHST- 2011/01/21 00:00 [accepted]
PHST- 2011/02/01 06:00 [entrez]
PHST- 2011/02/01 06:00 [pubmed]
PHST- 2011/06/21 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - S0003-2697(11)00055-8 [pii]
AID - 10.1016/j.ab.2011.01.028 [doi]
PST - ppublish
SO  - Anal Biochem. 2011 May 1;412(1):1-8. doi: 10.1016/j.ab.2011.01.028. Epub 2011 Jan 
      27.